ClinicalTrials.gg
CompletedNCT04062123MCAUpdated Apr 18, 2025Results posted

Memory & Conditioning Under Anesthesia

A Phase 1 interventional study of Dexmedetomidine and Propofol in Anesthesia and Pain, sponsored by Keith M Vogt. Completed at 1 site in United States. Open to participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-18.

Sponsored by Keith M Vogt · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies testing dexmedetomidine in Pain — 11 open to participants now, 12 under way, 2 of them phase 3. Dexmedetomidine · Pain.

Enrollment
23rd of 63
92 · median 70
Started
2020
the only one that year
Phase 1
7 of 64
none open now
Registered
30th of 64
by date

Among the 64 studies testing dexmedetomidine in Pain, this one is the 23rd largest by enrollment of the 63 interventional ones that give a count, is the only one that started in 2020, is one of 7 in phase 1, and was the 30th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

11 of the 64 studies testing dexmedetomidine in Pain are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 39 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing dexmedetomidine in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effects of pain on long-term memory and conditioned physiologic responses in the presence and absence of distinct intravenous anesthetics. Functional magnetic resonance imaging will be used to identify the neural correlates of these phenomena The study will occur over 5 visits and involves no long-term follow up.

Read the detailed description

Purpose: Sedative-hypnotic and analgesic agents (termed "anesthetics") are routinely used during medical procedures to prevent or ease suffering, suppressing the conscious experience of pain and its encoding into memory. While overt awareness under general anesthesia is a rare clinical event, implicit memory may still form. Further, at sub-hypnotic anesthetic doses, animals show enhanced fear conditioning and humans may have enhanced amygdala activity. This motivates the investigator's study, as poorly-contextualized aversive memories are theorized to initiate anxiety-spectrum disorders, which may explain the high incidence of post-traumatic stress disorder after anesthetic awareness.

Objective: How anesthetics facilitate or inhibit poorly-contextualized aversive memories is incompletely understood, with little mechanistic work done in human subjects. Thus, there is a critical need to understand how anesthetics modulate the memory and threat response systems during painful stimulation. The overall scientific objective is to determine the memory-modulating effects of propofol, dexmedetomidine, and fentanyl in the context of periodic painful stimulation.

Aim 1: Determine how behavioral and physiologic measures of memory are modulated by pain and the individual effects of three pharmacologically distinct drugs: propofol, dexmedetomidine, and fentanyl. Hypotheses: Based on previous results, 1a) explicit memory will be significantly reduced by propofol and dexmedetomidine, but only modestly by fentanyl. Consistent with my preliminary data, 1b) priming effects will be seen for pain-paired words under all drugs. Electrodermal activity changes still occur with opioids and propofol, thus 1c) pain-related physiologic responses will persist with these two drugs but be blunted by the anti-adrenergic effect of dexmedetomidine.

Aim 2: Determine the brain structures differentially engaged in memory encoding under pain and drug conditions. Task-related functional magnetic resonance imaging (MRI) activity for behavioral measures of explicit or implicit memory will be determined, comparing pain-paired vs non-pain items across drug and no-drug datasets. Functional connectivity (FC) MRI (fcMRI) will be compared between task and drug conditions. The entire brain will be explored, but predictions for key structures follow. Hypotheses: 2a) Hippocampal activity, will be blunted by propofol and dexmedetomidine, while fentanyl will have minimal effect. 2b) Amygdala activity, responsible for physiologic responses, will parallel the predictions in 1c across drug and pain conditions. 2c) Insula activity will be greater for pain-paired items, and this will be attenuated by fentanyl > dexmedetomidine > propofol, corresponding to their anticipated analgesic effect. 2d) Pain has been shown to affect fcMRI during a cognitive task, and thus FC between the key regions in 2a-c will be reduced by all three drugs, in characteristic patterns.

03

Conditions studied

  • Anesthesia
  • Pain

Browse trials for

Keywords

  • propofol
  • dexmedetomidine
  • fentanyl
  • functional MRI
  • electric nerve stimulation
  • sedation
  • functional connectivity
04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults, age 18-39, who are native English speakers with at least a high school education
  • have normal hearing and memory
  • be of normal body-weight
  • be generally healthy (free from significant chronic disease)
  • have none of the specific exclusion criteria
  • have a valid email address and valid phone number throughout the study
  • anticipate ability to participate in all visits required for the phase of the study in which they are enrolled

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • > 35 (obese) or \< 18 (underweight)
  • Use of psychotropic medications, including anti-epileptics, anti-psychotics, anxiolytics, anti-depressants, stimulants, sleep-aids, anti-histamines, or analgesics
  • History of adverse reaction to OR abuse of: dexmedetomidine (Precedex), propofol (Diprivan) or the opioids class of medications (fentanyl, morphine, hydromorphone, etc)
  • History of memory or hearing loss
  • History of obstructive sleep apnea
  • History of neurologic or psychiatric disease, including benign tremor
  • History of significant cardiac disease, including high blood pressure or arrhythmia
  • History of significant pulmonary disease
  • History of diabetes or neuropathy
  • History of chronic pain, or other pain processing disorder
  • Have an implanted medical electronic device
  • Have indwelling or implanted metal in their body that is not MRI-compatible
  • Have claustrophobia
  • Have a history of drug abuse
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Dexmedetomidine

    Subjects in this group will receive dexmedetomidine during the drug portion of the experiment.

    Drug: Dexmedetomidine · Device: Peripheral Nerve Stimulation · Drug: Placebo

  • Experimental
    Propofol

    Subjects in this group will receive propofol during the drug portion of the experiment.

    Drug: Propofol · Device: Peripheral Nerve Stimulation · Drug: Placebo

  • Experimental
    Fentanyl

    Subjects in this group will receive fentanyl during the drug portion of the experiment.

    Drug: Fentanyl · Device: Peripheral Nerve Stimulation · Drug: Placebo

Interventions

  • Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.15 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.

    Also known as: Precedex

  • Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.7 mcg/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.

    Also known as: Diprivan

  • Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.

    Also known as: fentanyl citrate

  • DevicePeripheral Nerve Stimulation

    Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the experimental cues.

    Also known as: Electric Nerve Stimulation

  • DrugPlacebo

    Crystalloid IV solution will be infused, with no active drug.

    Also known as: saline, IV fluid

06

What researchers measure

Primary outcomes

  1. Explicit Memory Performance

    Recognition memory testing, using the Remember-Know procedure, in which subjects indicate whether they recognize previously experienced experimental items among novel items (not previously in the experiment). This allows calculation of interdependent measures of recollection \& familiarity using the signal detection statistic, d'. d' is calculated as the cumulative Gaussian distribution of false positive responses subtracted from the cumulative Gaussian distribution of correctly identified previously-experienced items. d' is on a (theoretically infinite) scale of standard deviation units, with negative values representing performance worse than chance guessing and positive values representing stand deviations of performance above chance.

    Time frame: 24-hrs post-experiment

Secondary outcomes

  1. Brain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug Condition

    The Z-score is calculated by linear regression of the task timing against the MRI signal time-course (MRI data is in arbitrary units with no maximum or minimum) at each voxel (single data point in brain). The outcome is listed for the hippocampus, but similar scores are calculated throughout the brain. Z-score of 0 indicates no task-related changes. Z-scores further from zero indicate a larger difference in brain activity, with positive values indicating decreases under the drug condition, while negative Z-scores indicate increases under drug, compared to control. This outcome is reported as a number, as it is calculated using all the data across subjects combined into one statistical measure for the overall strength of difference in MRI signal change between two groups of data. Dispersion measures cannot be calculated for the summary Z-score.

    Time frame: Immediately after each experimental item

  2. Heart Rate Response

    Heart rate changes (measured by electrocardiogram, EKG) were planned to be determined following experimental stimuli that delivered as part of the experiment. A 1-6 second window of physiologic data will be analyzed for changes in the peak of the EKG response (R-wave), allowing calculation of instantaneous heart rate. Increases in heart rate are well-known to correlate to sympathetic nervous system activity increases.

    Time frame: Immediately after each experimental item

  3. Skin Response

    Electrodermal activity (galvanic skin) response was planned to be determined following experimental stimuli that delivered as part of the experiment. A 1-6 second window of physiologic data will be analyzed for changes in electrodermal activity, measured from the palm of subjects' hand. this well-established measure indicates sweat gland activity and is correlated to sympathetic nervous system activity increases.

    Time frame: Immediately after each experimental item

07

Results

Posted Apr 18, 2025

Participant flow

Participant flow — Overall Study
MilestonePropofolDexmedetomidineFentanyl
Started302933
Completed302833
Not completed010
Withdrew: Withdrawal by subject010

Outcome measures

PrimaryExplicit Memory Performance

Recognition memory testing, using the Remember-Know procedure, in which subjects indicate whether they recognize previously experienced experimental items among novel items (not previously in the experiment). This allows calculation of interdependent measures of recollection \& familiarity using the signal detection statistic, d'. d' is calculated as the cumulative Gaussian distribution of false positive responses subtracted from the cumulative Gaussian distribution of correctly identified previously-experienced items. d' is on a (theoretically infinite) scale of standard deviation units, with negative values representing performance worse than chance guessing and positive values representing stand deviations of performance above chance.

Time frame:
24-hrs post-experiment
Reported as:
Mean · units on a scale
Explicit Memory Performance
units on a scalePlacebo ControlPropofolDexmedetomidineFentanyl
Explicit Memory Performance1.16 (0.97 to 1.34).51 (0.182 to 0.842)1.04 (0.73 to 1.35).98 (0.68 to 1.28)
SecondaryBrain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug Condition

The Z-score is calculated by linear regression of the task timing against the MRI signal time-course (MRI data is in arbitrary units with no maximum or minimum) at each voxel (single data point in brain). The outcome is listed for the hippocampus, but similar scores are calculated throughout the brain. Z-score of 0 indicates no task-related changes. Z-scores further from zero indicate a larger difference in brain activity, with positive values indicating decreases under the drug condition, while negative Z-scores indicate increases under drug, compared to control. This outcome is reported as a number, as it is calculated using all the data across subjects combined into one statistical measure for the overall strength of difference in MRI signal change between two groups of data. Dispersion measures cannot be calculated for the summary Z-score.

Time frame:
Immediately after each experimental item
Reported as:
Number · Z-score for difference
Brain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug Condition
Z-score for differencePropofolDexmedetomidineFentanyl
Brain Activation in the Hippocampus for Successful Memory Formation: Placebo Condition Minus Drug Condition3.8-4.9-5.0
SecondaryHeart Rate Response

Heart rate changes (measured by electrocardiogram, EKG) were planned to be determined following experimental stimuli that delivered as part of the experiment. A 1-6 second window of physiologic data will be analyzed for changes in the peak of the EKG response (R-wave), allowing calculation of instantaneous heart rate. Increases in heart rate are well-known to correlate to sympathetic nervous system activity increases.

Time frame:
Immediately after each experimental item

No measurements were reported for this outcome.

SecondarySkin Response

Electrodermal activity (galvanic skin) response was planned to be determined following experimental stimuli that delivered as part of the experiment. A 1-6 second window of physiologic data will be analyzed for changes in electrodermal activity, measured from the palm of subjects' hand. this well-established measure indicates sweat gland activity and is correlated to sympathetic nervous system activity increases.

Time frame:
Immediately after each experimental item

No measurements were reported for this outcome.

Adverse events

Collected over Adverse event data was collected throughout the entire study period, at 5 study visits taking place over up to 3 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Propofol0/30 (0%)0/30 (0%)0/30 (0%)
Dexmedetomidine0/29 (0%)0/29 (0%)0/29 (0%)
Fentanyl0/33 (0%)0/33 (0%)2/33 (6.1%)
Most frequent other events
Most frequent other events
EventPropofolDexmedetomidineFentanyl
nauseaGastrointestinal disorders0/300/292/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)PropofolDexmedetomidineFentanylTotal
Mean25.0 ± 6.225.6 ± 6.523.9 ± 5.024.8 ± 5.9
Sex: Female, Male
Sex: Female, Male(Participants)PropofolDexmedetomidineFentanylTotal
Female14151645
Male16141747
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PropofolDexmedetomidineFentanylTotal
Hispanic or Latino1337
Not Hispanic or Latino22222771
Unknown or Not Reported74314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PropofolDexmedetomidineFentanylTotal
American Indian or Alaska Native0000
Asian56819
Native Hawaiian or Other Pacific Islander0000
Black or African American0033
White18171550
More than one race0246
Unknown or Not Reported74314
Region of Enrollment
Region of Enrollment(participants)PropofolDexmedetomidineFentanylTotal
United States30293392
08

Study locations

1 site
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Apr 2024, 44 months.

Results were first posted in Apr 2025, 11 months after primary completion.

Of 118 non-industry phase 1 interventional studies under Pain, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 44 months is above that.

Counting every sponsor, half of 222 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2019
First posted
Aug 20, 2019
StartActual
Jul 30, 2020
Primary completionActual
Apr 22, 2024
CompletionActual
Apr 22, 2024
Results first posted
Apr 18, 2025
Last update
Apr 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04062123
Lead sponsor
Keith M Vogt
Responsible party
Keith M Vogt (Associate Professor of Anesthesiology & Perioperative Medicine and Bioengineering, University of Pittsburgh) — Sponsor-investigator
First posted
Aug 20, 2019
Start date
Jul 30, 2020
Primary completion
Apr 22, 2024
Completion
Apr 22, 2024
Results posted
Apr 18, 2025
Last update
Apr 18, 2025

Study contacts

Keith M Vogt, MD, PhD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Propofol · Fentanyl

Start the discussion